secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061522
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation
--------------------------------------------------------------------------------

- Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.
- FDA granted Breakthrough Therapy Designation for MM120 in GAD, accelerating development and review.
- Company hosted conference call to discuss results and ODT PK bridging study data.
- MM120 is a proprietary sublingual formulation of lysergide targeting anxiety disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/0001193125-24-061522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000119312524061522/d788108d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer